Boston ScientificBSXEarnings & Financial Report
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Revenue
$5.1B
Gross Profit
$3.4B
Operating Profit
$819.0M
Net Profit
$795.0M
Gross Margin
67.7%
Operating Margin
16.2%
Net Margin
15.7%
YoY Growth
22.8%
EPS
$0.53
Boston Scientific Q2 FY2025 Financial Summary
Boston Scientific reported revenue of $5.1B (up 22.8% YoY) for Q2 FY2025, with a net profit of $795.0M (up 146.9% YoY) (15.7% margin). Cost of goods sold was $1.6B, operating expenses totaled $2.6B.
Key Financial Metrics
| Total Revenue | $5.1B |
|---|---|
| Net Profit | $795.0M |
| Gross Margin | 67.7% |
| Operating Margin | 16.2% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Boston Scientific Q2 FY2025 revenue of $5.1B breaks down across 10 segments, led by Medsurg at $1.7B (33.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Medsurg | $1.7B | 33.9% |
| Electrophysiology EP | $587.0M | 11.6% |
| Global Urologyand Pelvic Health Reporting Unit | $499.0M | 9.9% |
| Global Endoscopy Endo Reporting Unit | $456.0M | 9.0% |
| Watchman | $446.0M | 8.8% |
| Global Peripheral Interventions Pi Reporting Unit | $402.0M | 7.9% |
| Cardiac Rhythm Management | $355.0M | 7.0% |
| Interventional Cardiology Therapies | $252.0M | 5.0% |
| Global Neuromodulation Nm Reporting Unit | $228.0M | 4.5% |
| Other | $122.0M | 2.4% |
Boston Scientific Revenue by Segment — Quarterly Trend
Boston Scientific revenue by segment across the last 4 reported quarters, showing how each business line (such as Medsurg and Electrophysiology EP) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Medsurg | — | — | $1.7B | $1.7B |
| Electrophysiology EP | — | $606.0M | $607.0M | $587.0M |
| Global Urologyand Pelvic Health Reporting Unit | — | $521.0M | $511.0M | $499.0M |
| Global Endoscopy Endo Reporting Unit | — | — | $462.0M | $456.0M |
| Watchman | — | $485.0M | $470.0M | $446.0M |
Boston Scientific Annual Revenue by Year
Boston Scientific annual revenue history includes year-by-year totals (for example, 2025 revenue was $20.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $20.1B |
| 2024 | $16.7B |
Boston Scientific Quarterly Revenue & Net Profit History
Boston Scientific results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $5.2B | +11.6% | $1.3B | 25.7% |
| Q4 FY2025 | $5.3B | +15.8% | $670.0M | 12.7% |
| Q3 FY2025 | $5.1B | +20.3% | $755.0M | 14.9% |
| Q2 FY2025 | $5.1B | +22.8% | $795.0M | 15.7% |
| Q1 FY2025 | $4.7B | +20.9% | $672.0M | 14.4% |
| Q4 FY2024 | $4.6B | +22.5% | $563.0M | 12.3% |
| Q3 FY2024 | $4.2B | +19.3% | $468.0M | 11.1% |
| Q2 FY2024 | $4.1B | +14.5% | $322.0M | 7.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B |
| YoY Growth | 14.5% | 19.3% | 22.5% | 20.9% | 22.8% | 20.3% | 15.8% | 11.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $37.11B | $38.08B | $39.40B | $40.14B | $41.56B | $42.71B | $43.67B | N/A |
| Liabilities | $16.74B | $17.37B | $17.63B | $17.93B | $19.14B | $19.31B | $19.44B | N/A |
| Equity | $20.37B | $20.71B | $21.77B | $22.21B | $22.42B | $23.39B | $24.23B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $813.0M | $1.00B | $1.46B | $541.0M | $1.29B | $1.34B | $1.36B |